Qiagen N.V. Logo

Qiagen N.V.

Provides 'Sample to Insight' solutions for molecular analysis in research and clinical healthcare.

QIA | F

Overview

Corporate Details

ISIN(s):
DE000A286LP0 (+5 more)
LEI:
54930036WK3GMCN17Z57
Country:
Netherlands
Address:
HULSTERWEG 82, 5912 PL VENLO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Qiagen N.V. is a leading global provider of integrated "Sample to Insight" solutions designed to enable customers to gain valuable molecular insights from biological samples. The company's comprehensive portfolio covers the entire molecular testing workflow, from sample preparation technologies that isolate DNA, RNA, and proteins, to assay technologies and automated instrumentation for analysis. Qiagen also provides bioinformatics software to interpret the resulting data. Its products are utilized by a diverse customer base across molecular diagnostics, academic research, pharmaceutical development, and applied testing, facilitating advancements in life sciences and clinical healthcare.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 00:00
Foreign Filer Report
Q3 statement / Q3 financial report 2025
English 896.5 KB
2025-11-04 19:02
Board/Management Information
QIAGEN N.V.: QIAGEN announces CEO transition plan
English 6.5 KB
2025-09-30 11:25
Interim / Quarterly Report
Qiagen N.V., Halfjaarlijkse financiële verslaggeving
English 268.3 KB
2025-08-28 07:57
Capital/Financing Update
QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled converti…
English 18.4 KB
2025-08-22 00:00
Foreign Filer Report
Half-yearly financial report 2025
English 428.1 KB
2025-05-13 00:00
Foreign Filer Report
Q1 statement / Q1 financial report 2025
English 693.8 KB
2025-05-07 14:35
Notice of Dividend Amount
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for sharehold…
English 6.8 KB
2025-04-28 16:33
Annual Report (ESEF)
Qiagen N.V., Jaarlijkse financiële verslaggeving
English 23.4 MB
2025-04-06 18:20
Earnings Release
QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates fu…
English 7.2 KB
2025-03-31 00:00
Annual Report
Annual financial report 2024
English 6.2 MB
2025-02-06 06:31
Earnings Release
QIAGEN delivers solid Q4 2024 growth ahead of outlook
English 478.9 KB
2025-01-13 18:55
Transaction in Own Shares
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2025-01-12 18:55
Share Issue/Capital Change
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2024-11-07 07:30
Earnings Release
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024…
English 421.6 KB
2024-09-03 09:01
Capital/Financing Update
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
English 56.8 KB

Automate Your Workflow. Get a real-time feed of all Qiagen N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Qiagen N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Qiagen N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-17 S. Rusckowski Non-Executive member Other 26 N/A
2023-03-14 E.R. Mardis Non-Executive member Sell 4,739 218,422.41 USD
2023-02-28 E. Pisa Non-Executive member Other 7,917 N/A
2023-02-21 R. Sackers Non-Executive member Other 51,500 N/A
2022-12-01 R. Sackers Non-Executive member Sell 30,000 1,500,000.00 USD
2022-10-31 M. Colpan Non-Executive member Other 457 N/A
2022-06-08 R. Sackers Non-Executive member Sell 32,398 1,522,706.00 USD
2022-03-31 R. Sackers Non-Executive member Other 72,944 N/A
2022-03-15 R. Sackers Non-Executive member Other 7,606 N/A
2022-03-14 E.R. Mardis Non-Executive member Sell 5,003 228,330.77 USD

Peer Companies

Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
Atea Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
Athira Pharma, Inc. Logo
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL

Talk to a Data Expert

Have a question? We'll get back to you promptly.